Syndax Pharmaceuticals Inc (SNDX)

Over the past six months, Syndax Pharmaceuticals' stock price has experienced significant movements, with a 62.11% increase in value. In Q2 2025, Syndax reported a substantial GAAP revenue growth of 986% year-over-year, reaching $38.0 million, and narrowed its GAAP net loss per share to $(0.83). The company secured FDA approval for Niktimvo in August 2024 for the treatment of chronic graft-versus-host disease (cGVHD). Revuforj was approved in November 2024 for certain relapsed or refractory acute leukemias, and received a second FDA approval for NPM1-mutated Acute Myeloid Leukemia (AML) on October 24, 2025, and was included in NCCN Clinical Practice Guidelines for AML treatment in September 2025. The stock experienced an approximate 8% decline due to investor apprehensions surrounding an expanded boxed warning. Michael Metzger, CEO of Syndax Pharmaceuticals, sold 7,412 shares of the company's stock for a total of $152,835.44. Syndax reported preliminary unaudited net revenue of approximately $44 million for Revuforj in Q4 2025 and $125 million for the full year 2025, and Niktimvo contributed approximately $56 million in Q4 2025 and $152 million for the full year 2025 in preliminary unaudited net revenue.

There is no specific information available to indicate significant demand seasonality for Syndax Pharmaceuticals, Inc.'s products and services. The company's focus is on developing and commercializing therapies for serious diseases like cancer, where demand is typically driven by medical need and treatment protocols rather than seasonal fluctuations.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company transitioning to a commercial-stage oncology innovator, dedicated to developing innovative therapies for cancer and other serious diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company operates primarily within the biopharmaceutical sector, focusing on oncology and immuno-oncology. Syndax's major products include Revuforj (revumenib), a menin-MLL1 inhibitor approved for certain acute leukemias; Niktimvo (axatilimab-csfr), a monoclonal antibody developed for chronic graft-versus-host disease (cGVHD) and other fibrotic diseases; and Entinostat (SNDX-275), a selective HDAC inhibitor in late-stage clinical trials for hormone receptor-positive breast cancer and other solid tumors.

Syndax Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts, in the United States. The company has also established wholly-owned subsidiaries in the United Kingdom and the Netherlands, although these entities have not had material activities to date. Syndax and World Orphan Drug Alliance are launching a multi-regional managed access program to expand access to Revuforj outside the U.S., covering parts of Eurasia, Central and Southeast Europe, Israel, the Middle East and Turkey, Latin America, and Africa.

Syndax Pharmaceuticals has maintained a positive brand reputation over the past year, largely driven by its clinical advancements and product approvals. Revuforj was named "Best New Drug" at the Scrip Awards 2025. The company has garnered strong analyst support, with a consensus "Buy" rating from 11 analysts and an average target price of $34.18. There is positive sentiment among physicians regarding frontline treatment options and the early commercial success of Revuforj.

Syndax Pharmaceuticals, Inc. has a significant institutional ownership base, with 364 institutional owners holding a total of 108,886,509 shares as of Q4 2025. Major institutional shareholders include BlackRock, Inc., Kynam Capital Management, LP, Vanguard Group Inc, Goldman Sachs Group Inc, Point72 Asset Management, L.P., State Street Corp, Bank Of America Corp /de/, Eversept Partners, LP, and Adage Capital Partners Gp, L.l.c. Individual insiders hold approximately 0.544% of the shares, totaling 556,482 shares.